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Abstract  With an ageing population, the number of 
age-related macular disease (ARMD) cases will inev- 
itably rise. This gives greater impetus for the need to 
identify the disease earlier and assess treatments to 
slow disease progression. Differing electroretinogram 
(ERG) modalities have been reviewed in relation to the 
objective assessment of retinal function in ARMD and 
for monitoring the effectiveness of clinical interven- 
tions. Conflicting results have been found with regard 
to the efficacy of ERG findings in the investigation of 
ARMD in previous years. The newer multifocal ERG 
paradigm provides spatial topographical information 
about retinal function in ARMD. It has shown 
promising results in monitoring effectiveness of 
clinical interventions and studies are continuing in 
this area. Better knowledge of retinal function in 
ARMD may lead to enhanced treatments at each phase 
of the disease. 
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Introduction 
 
In the majority of clinical studies of ARMD, visual 
acuity is used as a measure of macular function. 
However, this is far from ideal as it assesses one small 
area of the retina, does not provide an overall measure 
of macular function and relies on subjective patient 
responses. It is important to identify individuals who 
are at most risk of developing the ARMD, so that 
interventions and lifestyle modifications can be 
targeted appropriately. In asymptomatic eyes, sensi- 
tive, reproducible measures of macular function are 
important to highlight the earliest signs of ARM. The 
objectivity and the topographical mapping that mul- 
tifocal electroretinography (mfERG) provides allows 
for assessment of localised retinal cell function 
deficits in ARM over time. Evidence also suggests 
that mfERG can be used to monitor effectiveness of 
surgical and clinical intervention. This review enu- 
merates the efficacy of various types of electroretino- 
gram (ERG) for assessing retinal function in ARMD. 
Age-related macular degeneration (AMD) is the 
leading cause of visual loss in the developed world 
[1]. Age-related maculopathy (ARM) is characterised 
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by drusen (C63 lm) with or without retinal pigment 
epithelium (RPE) changes and often precedes AMD. 
The term ‘age-related macular disease (ARMD)’ 
encompasses both ARM and AMD [2]. 
The RPE phagocytises the outer segment discs of 
the photoreceptors and is a point of metabolite and 
waste exchange, which is considered crucial to retinal 
function [3]. The earliest signs of ARMD are seen as 
variation  in the pigmentation of the RPE, with or 
without the presence of drusen [4]. Oxidative stress 
may cause injury and inflammation to the RPE and 
choriocapillaris leading to an altered extracellular 
matrix, affecting nutrient supply to the RPE and 
retina, possibly further damaging the RPE and retina, 
leading to the retinal atrophy seen in AMD [5]. 
Ophthalmic electrophysiology can be used to mea- 
sure the function of the choroid, RPE and the 
photoreceptor layer [6] and has therefore been shown 
to be a good means of objectively quantifying retinal 
function. RPE changes seen in AMD can be mea- 
sured  by  the  electrooculogram (EOG). Electroreti- 
nography assesses photoreceptor and post-receptoral 
retinal function. The differing ERG techniques are 
easily and non-invasively obtained with an active 
corneal electrode, reference electrode and ground 
electrode where electrical activity within the retina is 
studied using presentation of visual stimuli. Different 
stimuli used for differing ERG techniques allow for 
functional quantification of various retinal cells, each 
of which is discussed in the following sections. 
 
 
Full-field electroretinogram (ERG) 
 
The   full-field  or   flash  ERG   (ffERG)   generally 
consists of a negative deflection, called the a-wave, 
which is mainly associated with the photoreceptors 
and a positive b-wave, thought to be produced by ON 
bipolar cell depolarisation. Scotopic ffERGs elicit 
rod–dominated photoreceptor function responses and 
photopic conditions elicit cone-function responses. A 
30-Hz light stimulus ERG also provides information 
about cone function, whilst oscillatory potentials 
reflect amacrine cell function [7]. ARMD can subtly 
affect areas of the retina unseen on clinical fundos- 
copy due to generalised retinal ischaemia [8] and 
altered retinal nutrient and waste exchange [5], thus 
ffERG changes may be apparent when ophthalmos- 
copy findings show very little. 
The ffERG gives a massed retinal electrical 
response to  a  light  stimulus but  does  not  provide 
spatial retinal information. Thus, small retinal lesions 
such as those seen in ARM may be missed by ffERG, 
and so there have been contradictory findings reported 
for the appropriateness of using ffERG in the assess- 
ment of the condition [9–12] Holopigian et al. exam- 
ined the effect of normal ageing, ARM and AMD on 
the ffERG. They demonstrated reduction of ampli- 
tudes and increase in implicit times of the ffERG over 
time with increasing age for normal subjects, as well 
as those with ARM and AMD under photopic and 
scotopic conditions [12]. Similarities between older 
normal subjects and those with ARM highlight the 
importance of using age-matched normals for com- 
parison when observing older subjects with ARMD. 
These results correlated  with the findings of other 
studies showing a  decrease  in  rod and cone  ERG 
amplitudes with age [13] and a slowed inactivation of 
phototransduction in rod photoreceptors with age 
when measuring the recovery of the a-wave using a 
paired flash ERG technique [9]. Marcus et al. [11] 
studied  the  b-wave of  the  ERG in  24 eyes of  12 
subjects with ARMD and found low to normal b-wave 
amplitudes in diseased eyes and no correlation with 
clinical morphology. However, there was no control 
group comparison. 
Along with reduced and delayed photopic cone- 
dominated a-wave responses, scotopic rod-dominated 
a- and b-wave responses have been examined in 
ARMD using the ffERG. These were also reduced 
and delayed, suggesting that ARMD affects rod as 
well as cone photoreceptors [10]. A review by 
Scullica  and  Falsini [14]  identified that  studies  of 
retinal function in ARM and AMD have found 
substantial impairment of rod photoreceptor function. 
Inconsistency exists in the literature about the value 
of ffERG in ARMD. As the ffERG is a massed 
response, the sensitivity of the test is limited when 
trying to assess small lesions as observed in ARM 
[15]. 
 
 
Pattern ERG 
 
The pattern ERG (PERG) occurs with pattern reversal 
stimulation, typically a checkerboard pattern of mean 
overall luminance, which isolates non-linear retinal 
responses while cancelling linear responses [16]. This 
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gives a direct measure of ganglion cell function and 
allows discrimination between optic nerve and mac- 
ular  disease [17]. Pattern ERG abnormalities have 
been seen in AMD and reduced PERG P50 ampli- 
tudes have been observed in maculopathies [17]. The 
PERG has been shown to be abnormal in macular 
dysfunction when there is no detectable change in the 
ffERG [18]. Since the PERG measures ganglion cell 
function [17] and ganglion cell function remains 
relatively preserved in AMD [19], it may be argued 
that PERG does not provide sufficient information 
about retinal function in ARMD, especially in ARM 
when only small areas of drusen are seen. The PERG 
elicits an inner retinal response whereas ARMD is a 
retinal degeneration primarily affecting the RPE and 
the choriocapillaris [12]. 
The PERG has been effective at assessing retinal 
function in AMD when clinical interventions are 
undertaken. Neveu et  al. [20] demonstrated that  a 
detectable PERG prior to photodynamic therapy 
(PDT) in eyes with choroidal neovascularisation 
(CNV) was the single best indicator for improvement 
in visual acuity following treatment. However, in 
ARM, the area of retinal lesion is usually smaller than 
the area of PERG recording making the PERG less 
effective at monitoring ARM compared to angiogra- 
phy. The PERG fails to provide any spatial retinal 
information. Another study examining PERG at the 
early stages of PDT for CNV showed a reduction in 
amplitudes and delay in latencies of the P50 and N95 
soon  after  PDT  which  resolved  at  1 month  [21]. 
Mackay et al. [19] assessed longer term changes to 
the PERG over 12 months and found that the P50 and 
N95 amplitude reduced over the 12 months, without 
recovery. The P50 latency reduced over the year but 
then increased at 12 months. However, this finding 
was not statistically significant. 
 
 
Focal ERG 
 
Unlike the ffERG, the focal ERG (fERG) has the 
ability to specifically stimulate the fovea—useful 
when evaluating macular disease [22, 23]. A flicker- 
ing light stimulus is utilised to stimulate the macular 
region and measures macular cone photoreceptor and 
bipolar cell function [24]. Although there is no 
international procedural standard set for undertaking 
this ERG technique, a number of varying techniques 
for recording fERG have been described in the 
literature.  Differing  field  sizes  (3 –18 )  and  light 
stimulus frequencies have been used. Seiple et al. [25] 
examined retinal function in ARMD using a range of 
stimulus frequencies (10–60 Hz). This work showed 
fERG amplitude losses at high and low frequencies in 
patients with macular disease, but relative sparing of 
the mid-temporal frequencies although the type and 
severity of ARMD was not noted within the results or 
separated out from other macular diseases. 
Research on fellow eyes of patients with unilateral 
CNV has suggested that these eyes have a normal 
foveal cone number but abnormal cone function, 
indicated by delayed implicit times. Results were 
adjusted for age, gender, iris pigmentation and 
spherical equivalent [26]. Another study confirmed 
these findings and is postulated to be due outer retinal 
ischaemia [27]. Normal fERG phase but decreasing 
amplitudes  have  been  documented  with increasing 
severity of non-exudative AMD [28]. 
Nutritional supplementation and its effects on 
macular function have been investigated in subjects 
with ARM and age-matched normals. Falsini and 
colleagues [29] found that at 180 days, normal and 
ARM eyes showed an increase in fERG amplitudes 
after vitamin E and nicotinamide supplementation. At 
360 days, amplitudes were maintained. 
Binns and Margrain [30] proposed a fERG photo- 
stress modality to examine retinal function in ARM, 
using intense light adaptation to bleach the retina, 
followed by periodical fERG to examine the recov- 
erability of retinal function and determine the rate of 
photopigment regeneration. Retinal function recovery 
rate  was  slower in  those  with  ARM  compared  to 
controls suggesting impairment in the ability of the 
outer retina to regenerate cone photopigment. 
The effect of age on the fERG has been detailed, 
showing decreasing  amplitude  with  increasing  age 
[23,  26] and increasing fERG implicit  times [26], 
stressing the need for age-matched controls when 
investigating ARM and AMD with fERG. 
Focal ERG is useful for assessing retinal function 
in ARM and AMD. However, good fixation is 
required and it is limited to a single area, thus giving 
no information about multiple areas of retinal func- 
tion. Also, no international procedural standard has 
yet been determined. 
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Multifocal  ERG 
 
The multifocal ERG (mfERG), developed by Sutter 
and   Tran   [31],   is   based   on   a   pseudorandom 
M-sequence stimulation technique that allows simul- 
taneous recording of ERGs from many retinal areas at 
once [32]. Like PERG, fERG and ffERG, it is an 
objective measurement of retinal function but in 
contrast  to  these  tests the  mfERG allows simulta- 
neous measurements of multiple responses at differ- 
ent retinal locations [33, 34]. The first-order kernel of 
the mfERG waveform comprises of a negative N1 
component, a positive P1 component and a negative 
N2 component. Hood’s very comprehensive literature 
on  mfERG  suggests  that  mfERG  responses  are 
similar to the ffERG in that the N1 of the first-order 
kernel of the mfERG is cone-driven (as in a photopic 
ffERG) and that the P1 contains responses from the 
bipolar cells [35]. The mfERG is dominated by 
bipolar cell activity and so a disease that substantially 
decreases the mfERG amplitude must therefore be 
acting at or before the bipolar response [7]. The first- 
order kernel is the most commonly measured param- 
eter of the mfERG. The mfERG also contains a 
second order kernel which originates from induced 
components of the inner retina, more details of which 
can  be  understood in  the  work of  Sutter [36–38]. 
The mfERG maps retinal function within the central 
30 –50  of the retina and good fixation is required for 
accurate results, suggesting it may be better suited to 
assessment of retinal function in ARM where central 
vision is preserved. 
Various studies have reported the efficacy of the 
mfERG in the assessment of ARMD [6, 19, 20, 29, 
33, 39–58]. 
Eyes with ARM have been found to have reduced 
foveal mfERG P1 amplitudes and increased N1 
latencies when compared with age-matched normal 
controls [46]. Interestingly, asymptomatic fellow eyes 
of the ARM eyes in this study also exhibited the same 
findings, suggesting that the mfERG may be a sensitive 
means of detecting early ARM changes. Feigl et al. 
[59], in contrast, found no such correlation, possibly 
attributable to non-uniform use of grading and classi- 
fication systems and varying age range of the partic- 
ipants used in the different studies. 
Research comparing the mfERG between exuda- 
tive AMD, non-exudative ARM and normal controls 
has been undertaken [44] demonstrating reduction in 
the P1 and N1 amplitudes of both CNV and ARM eyes 
when compared with controls. However, although the 
average age of the CNV and ARM groups were 
similar  in  this study (64.4 and 66.5 years, respec- 
tively), the control group was younger (57.7 years). 
This may account for some amplitude reduction due to 
ageing influence on the mfERG [60, 61]. Seiple et al. 
[62] demonstrated a significant linear relationship of 
10.5% reduction in the N1 to P1 amplitude per decade, 
emphasising the importance of using age-matched 
controls when interpreting mfERG results. 
The mfERG guidelines described by the Interna- 
tional   Society  for  Clinical  Electrophysiology  of 
Vision (ISCEV) [63], measures cone function. How- 
ever, rod-mediated mfERG can be recorded after dark 
adaptation. It is time consuming with poorer signal- 
to-noise ratios than cone-mfERGs [64]. A study to 
compare  rod- and cone-mediated mfERG in ARM 
showed reduced N1 and P1 amplitudes in ARM when 
compared to controls in both rod- and cone-mediated 
mfERGs [47]. Delayed rod-mediated mfERG P1 
implicit times in ARM eyes were reported when 
compared with age-matched normal controls [50, 52, 
53], implying that both rod and cone function is 
affected in ARM. However, further work using larger 
sample sizes would provide more definitive rod- 
mfERG  information,  as  to  date  conflicting results 
have been demonstrated. 
Interesting work has been undertaken on the use 
mfERG to investigate the role of ischaemia in ARM. 
Hypoxia has been experimentally induced in younger 
and  older healthy  eyes resulting in  a  reduction in 
central and peripheral neuroretinal function indicated 
by reduced mfERG response densities [41, 65, 66]. 
This supports the hypothesis that post-receptoral 
vulnerability occurs during reduced oxygenation and 
ischaemia [52, 67]. 
Differing mfERG paradigms have  been  used to 
evaluate rod and cone systems in ARM. Global-flash 
mfERGs have been used in an attempt to overcome 
some of the conflicting findings that have been 
observed with the conventional mfERG and to better 
reflect adaptation deficits in ARM [51]. The findings 
indicate that the global-flash mfERG detects reduced 
adaptation responses before the conventional mfERG. 
Thus,  it  could be  argued that  global-flash mfERG 
may be more beneficial in identifying ARM sooner 
than the standard mfERG. More research is necessary 
to consolidate this hypothesis. 
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The slow flash mfERG is another paradigm that 
has been subtracted from the conventional fast flicker 
mfERG to assess non-linear adaptive components 
within the retina in ARM [48]. Interestingly, neither 
conventional  mfERG  nor  slow  flash mfERGs  dis- 
criminated between the ARM group and age-similar 
controls. However, the difference between the two 
paradigms showed a reduced late component wave- 
form  in  the  ARM  group  compared  to  the  control 
group suggesting post-receptoral adaptation abnor- 
malities in the ARM group. 
Comparison between the conventional cone-mediated 
mfERG response and morphological changes in ARM 
have been examined [40, 49, 68], with outcomes 
suggesting slight increase in delayed implicit time with 
drusen progression, drusen regression with  increasing 
RPE changes and in stable drusen. After  more than 
2 years,  the  responses  became  more  delayed  with 
reduced response density. The mfERG changes were 
not limited to the drusen areas in these studies, suggesting 
retinal function does not correlate directly with morphol- 
ogy in ARM. 
The objectivity of the mfERG in assessing retinal 
function correlates well with subjective macular 
function tests in ARM and AMD [39], such as colour 
vision [49] and microperimetry testing [69] and 
suggests they may be significantly related to retinal 
function in the cone-mediated mfERG in ARM. 
 
 
Multifocal  ERG in clinical intervention studies 
 
mfERG has been investigated as a tool for assessing 
retinal function before and after PDT, a widespread 
treatment for predominant classic CNV prior to the 
introduction of intravitreal ranibizumab and bev- 
acizumab (Table 1). 
Palmowski et al. [57] compared retinal function 
pre- and post-PDT in 16 eyes and found that after 
PDT the mfERG showed focal improvements in 13 
eyes. In 10 eyes, focal retinal function deteriorated in 
some  locations.  At  15 weeks,  some  areas  of  the 
mfERG did not demonstrate any improvement when 
compared with mfERGs obtained at 3 weeks post- 
PDT. They concluded that improvement in parafo- 
veal function can be seen with mfERG and deemed it 
a suitable tool in assessing retinal function in AMD. 
Short-term mfERG changes were assessed in 17 
eyes with CNV before and after PDT with verteporfin 
by Jiang et al. [56] The mfERG latencies and response 
amplitude densities remained largely unchanged 
within 3 days, and at 1 week post-PDT with verte- 
porfin when compared with pre-PDT mfERG. Their 
data suggests that verteporfin therapy may not result 
in adverse effects within the outer retina, in contrast to 
other histopathological studies assessing verteporfin 
and PDT in the monkey retina [70]. 
Multifocal ERG recordings were performed before 
PDT, and at 4 days, 2 weeks and 1 month after PDT 
with verteporfin in a study by Lai et al. [42]. Their 
research showed a transient impairment in retinal 
function that resolved after 1 month. In contrast to 
the work by Jiang et al., there was a change at 4 days 
post-PDT with reduced N1 and P1 response ampli- 
tude densities and increased P1 latencies. However, 
Lai’s study contained only three AMD eyes with 
CNV,  the  other  fourteen eyes  being  a  mixture  of 
myopic CNV, idiopathic CNV, polypoidal choroidal 
vasculopathy and central serous chorioretinopathy. 
Studies at baseline and 6 weeks post-PDT were 
assessed with mfERG by Ruether et al. [71] showing 
a trend towards reduced P1 amplitudes and delayed 
latency, although these effects were not statistically 
significant and comparison to a non-treated group did 
not occur. 
Catala-Mora et al. [72] observed mfERG changes 
over a longer period post-PDT in twenty-three eyes. 
At two and six months after treatment, the N1 and P1 
amplitudes did not change and even improved in the 
more  peripheral areas  tested.  They  concluded  that 
mfERG offers interesting non-subjective information 
about retinal sensitivity in macular diseases treated 
with PDT. 
Mackay et al. [58] examined the use of mfERG as 
a predictor of vision maintenance post-PDT in 
neovascular AMD using logistic regression models. 
Patients with an  average  of 6/30 vision were less 
likely to respond to PDT than those with poor vision. 
Relatively good contrast sensitivity and large central 
mfERGs increased the probability of a response to 
PDT. In a further study, mfERG was assessed in pre- 
and post-PDT in CNV. They found P1 response 
amplitude  density  increased  at  6 months  and  then 
returned to baseline at 12 months [19]. Work under- 
taken by Moschos et al. [73] demonstrated that 
although  at   6 months  post-PDT  70%   of   vision 
remained stable, there was a demonstrable reduction 
of mfERG response amplitude density, highlighting 
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Reference Sample size Age in years 
Mean/range 
ARMD status Visual acuity 
pre-PDT 
Mean mfERG 
findings pre-PDT 
Follow-up 
duration after 
PDT 
Visual acuity 
post-PDT 
Mean mfERG 
findings post- 
PDT 
Palmowski et al. Influence 16 eyes of 16 Not stated Classic Median 0.2 Scalar product (SP) 2–15 weeks Median 0.3 SP improved in 
of photodynamic therapy
in choroidal 
neovascularization on 
focal retinal function 
assessed with the 
multifocal 
electroretinogram and 
perimetry. 
Ophthalmology. 2002; 
109(10):1788–92. 
patients  neovascular
AMD 
range
0.05–0.8 
template used
thus no pre-PDT 
mfERG 
information given 
 range
0.04–1.25 
16 locations 
SP reduced in 
11 locations 
Jiang et al. The changes of 17 eyes of 16 55.2 (25–76) 12 exudative Median 20/ Ring 1–6 N1 lat 3 days, Median  20/25 Ring 1–6 N1 lat 
multifocal patients AMD eyes 25 21.39 7 days range 20/ 21.58 
electroretinography in
the early stage of   
(11 cases)
2 myopic CNV 
Range 20/ 
25–20/125 
Ring 1–6 P1 lat 
40.29  
25–20/125 Ring 1–6 P1 lat 
40.39 
for choroidal 3 idiopathic Ring 1–6 N1 amp Ring 1–6 N1 
D
oc O
phthalm
ol
1
2
3
 
Table  1  A summary of post-PDT mfERG studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
photodynamic therapy 
 
neovascularization. 
Documenta 
Ophthalmologica. 2003; 
107(2):165–70. 
Ruether et al. Testing 
central retinal function 
with multifocal 
electroretinography 
before and after 
photodynamic therapy. 
Ophthalmologe. 2003; 
100(6):459–64. 
 
 
 
 
 
 
25 eyes of 24 
patients 
 
 
 
 
 
 
71.3 range 
not given 
 
 
CNV 
 
 
 
 
12 classic 
subfoveal 
Neovascular 
AMD 
9 Occult CNV 
AMD 
4 myopic CNV 
 
 
 
 
 
 
Mean 0.22 
range not 
given 
 
 
7.84 
Ring 1–6 P1 amp 
17.44 
 
Centre amp 31.33 
Ring 1 amp 20.67 
Ring 2 amp 15.33 
 
 
 
 
 
 
6 weeks Mean 0.22 
range not 
given 
 
 
amp 7.91 
Ring 1–6 P1 
amp 17.63 
(at 7 days) 
Centre amp 
26.33 
Ring 1 amp 
18.33 
Ring 2 amp 
13.33 
Moschos et al. Assessment 20 eyes of 20 69.05 (range Classic Mean 21.35 Mean retinal 1 week, 17.6 range Mean retinal 
of macular function by patients 30–80) subfoveal range 1–49 response amp 3 months, 1–42 response amp 
multifocal neovascular (ETDRS density area 6 months (ETDRS density area 
electroretinogram  in age- AMD number of 1 = 4.39, area number of 1 = 2.24 area 
related macular letters) 2 = 2.11 letters) 2 = 1.07 
degeneration  before and  
after photodynamic
therapy. J Fr Ophthamol.
[Article].  2004 Nov;
27(9):1001–6. 
Table  1  continued  
Reference Sample size Age in years ARMD status Visual acuity Mean mfERG Follow-up Visual acuity Mean mfERG 
  Mean/range  pre-PDT findings pre-PDT duration after
PDT 
post-PDT findings post-PDT 
Lai et al. Transient 17 eyes 50.5 (29–75) 3 AMD CNV Median  20/ Central  N1 amp 9.97 4 days, Median 20/50 Central N1 amp 9.49 
reduction  in retinal of 17 4 idiopathic 70 range Peripheral  N1 amp 2 weeks range 20/ Peripheral  N1 amp 6.52 
D
oc O
phthalm
ol 
1
2
3
 
 
 
 
 
 
 
 
function  revealed by 
multifocal 
electroretinogram after 
photodynamic therapy. 
American Journal of 
Ophthalmology. 2004; 
137(5):826–33. 
patients CNV 
4 myopic CNV 
4 polypoidal 
choroidal 
vasculopathy 
2 central serous 
chorioreti- 
nopathy 
20/30–20/ 
100 
6.93 
Central P1 amp 26.12 
Peripheral  P1 amp 
19.40 
and 
1 month 
30–20/100 
at 1 month 
 
Central P1 amp 25.05 
Peripheral  P1 amp 18.81 
(at 1 month) 
Feigl B et al. Dynamics of 
retinal function after 
multiple photodynamic 
therapies in age-related 
macular degeneration: A 
report of cases. Doc 
Ophthalmol. 2005 Apr 
24–29; 111(3):135–48. 
5 eyes of 5 
patients 
74 (64–81) 5 CNV AMD Median 6/38 
range 
6/19–6/60 
Pre-treatment figures 
not provided. Pre- 
treatment mfERG 
used as a waveform 
template with 
Matlab software to 
compare with post- 
treatment mfERG 
values 
1,2 and 
3 months 
Median 6/48 
range 6/38– 
6/60 
Cone-mfERG: Central a-
scale = 1.0 paracentral a-
scale = 1.3 pericentral a-
scale = 1.3 central t-scale 
= 1.1 paracentral t-scale 
= 1.0 pericentral t-scale 
= 0.9 (all numbers are 
ratios at 
3 months compared to 
pre-treatment values) 
Rod-mfERG: 
Overall  a-scale = 0.9 
Overall  t-scale = 0.9 
(all numbers are ratios at 
2 months compared to 
Catala-Mora  et al. 23 eyes of 22 Not given 23 classic 20/21 See post-PDT 2 months, 20/17 
pre-treatment values) 
Statistical significance 
Multifocal patients CNV AMD (colenbr- column 6 months (colenbr- was reached for ring 5 
electroretinogram  and ander) ander) at scalar product, ring 3 
age-related  macular 6 months and ring 5 P1 
degeneration.  Arch Soc amplitude,  ring 3 P1 
Esp Oftalmol. 2005; latency and in ring 5 
80(7):395–404. N1 latency at 6 months 
compared  to pre 
        treatment values 
Mackay et al. Multifocal 39 eyes of 39 77.1 (74.7– 34 classic CNV Median 48.0 Ring 1 P1 amp 18.5 12 months 59% lost less Not undertaken— 
electroretinography as a patients 79.1) AMD letters Ring 2 P1 amp 19.6 (VA not than 15 mfERG undertaken 
predictor of maintenance 5 classic with logMAR mfERG) letters on prior to PDT as a 
of vision after occult 
photodynamic  therapy Ring 1 P1 lat 39.5 
for neovascular age- Ring 2 P1 lat 37.8 
related macular Ring 3 P1 lat 35.7 
degeneration. 
Documenta 
Ophthalmologica. 2008;
the ETDRS predictor  for vision 
chart over maintenance  post- 
12 months PDT. Large central 
mfERGs prior to PDT 
increase the probability 
of a response to PDT in 
neovascular  AMD 
D
oc O
phthalm
ol
1
2
3
 
Table  1  continued 
 
Reference  Sample size Age in years 
Mean/range 
 
 
ARMD status Visual acuity 
pre-PDT 
 
 
Mean mfERG 
findings pre-PDT 
 
 
Follow-up 
duration after 
PDT 
 
 
Visual acuity 
post-PDT 
 
 
Mean mfERG 
findings post-PDT 
 
Mackay et al. Deficits in 
the electroretinogram in 
neovascular age-related 
macular degeneration 
and changes during 
photodynamic therapy. 
Documenta 
Ophthalmologica. 2007; 
115:69–76. 
 
50 eyes of 50 
patients 
plus 13 
control eyes 
 
77.5 (61–92) 
Patient 
72.8 (56–88) 
control 
 
43 classic CNV 
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Pre-PDT 
Central segment amp 
deficit 59.7 
Ring 2 amp deficit 
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when compared to 
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Post-PDT the deficits 
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at 12 months 
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the need for objective measures of retinal integrity 
when monitoring the efficacy of clinical intervention. 
Feigl et al. used the rod-mfERG and cone-mfERG 
to determine the effects of multiple PDT treatments 
in a case report of five eyes showing transient 
reduction in cone-mfERG waveforms and then 
recovery over time in all eyes and similar findings 
for  rod-mfERG  in  four  out  of  five eyes,  possibly 
caused by choroidal hypoperfusion. However, base- 
line rod-mfERG responses were poor, very small and 
the test demanding for patients [74]. 
With the recent implementation of costly intravi- 
treal ranibizumab treatment for AMD with CNV, 
greater impetus has been given to looking at ways of 
diagnosing, monitoring and treating AMD earlier to 
preserve vision. In a study of nine patients who 
received intravitreal bevacizumab for the treatment of 
exudative AMD, mfERGs were performed pre- and 
post-treatment [55]. A linear relationship was found 
between visual acuity and P1 response amplitudes, 
suggesting that bevacizumab improved retinal func- 
tion. mfERG parafoveal retinal response density 
improvement 3 months post-bevacizumab has been 
demonstrated in research by Moschos et al. [75] when 
studying eighteen eyes with CNV. Correlation 
between mfERG retinal response density in the central 
fifteen degrees and retinal thickness has been demon- 
strated in four eyes post-bevacizumab treatment, 
resulting in improvement of mfERG macular function 
responses with reduction in retinal thickness as 
measured by optical coherence tomography, although 
in this study ISCEV mfERG guidelines were replaced 
with a customised experimental m-sequence technique 
[76]. Ranibizumab efficacy has been investigated in a 
small study of three eyes using mfERG with a 
reduction in central and peripheral amplitudes being 
evident after three treatments when compared to age- 
matched normal eyes [77]. Further studies are required 
in the area of anti-vascular endothelial growth factor 
(anti-VEGF) agents, both singularly and in combina- 
tion treatments, to test the efficacy of different dosing 
regimes and the mfERG could have an important role 
for assessing retinal function within this area. 
The role of nutrition in retinal health may prove to 
become an integral part in the management of ARM. 
Parisi et al. [54] looked at the influence of short-term 
carotenoid and antioxidant supplementation on retinal 
function in ARM. They demonstrated that in the 
central  five  degrees,  ARM  subjects  treated  with 
nutritional supplementation showed an increase in 
mfERG amplitudes after 6 months when compared 
with controls. 
 
 
Conclusion and future  directions 
 
It is important to identify individuals who are at most 
risk of developing the ARMD, so that interventions and 
lifestyle modifications can be targeted appropriately. 
In asymptomatic eyes with normal visual acuity, 
sensitive but reproducible tests of macular function 
will become more important to detect the earliest signs 
of ARM. The objectivity and the topographical map- 
ping of the mfERG allow localised retinal functional 
deficits in ARM can be observed over time. Evidence 
also suggests that mfERG can be used to monitor 
effectiveness of surgical and clinical intervention. 
Experimental mfERG techniques as discussed, have 
shown some interesting findings and although exper- 
imental at this stage, may provide additional informa- 
tion about the onset and progression of ARM with time. 
Complementary subjective measurement techniques 
such as microperimetry may document disease pro- 
gression and treatment monitoring in macular function 
more effectively than visual acuity alone [78]. 
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